LONDON (Alliance News) - ANGLE Plc said Tuesday that "highly encouraging results" have been published by Cancer Research UK Manchester Institute from its work in lung cancer using ANGLE's Parsortix system.
The results were published in the Royal Society of Chemistry's publication Analyst.
Parsortix works by separating and harvesting cells from a patients blood that can be used to identify cancer. The work undertaken by Cancer Research UK Manchester Institute compared Parsortix with CellSearch, the only other circulating tumour cell technology that has currently been approved by the US Food and Drug Administration.
"This is our second peer-reviewed publication in a scientific journal and adds to the growing body of published evidence of Parsortix's performance as a liquid biopsy," said Chief Executive and Founder Andrew Newland in a statement.
Shares in ANGLE were up 1.3% at 77.00 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Angle (AGL)